Geron (GERN) Free Cash Flow (2010 - 2026)
Geron's (GERN) quarterly Free Cash Flow came in at -$62.9 million in Q1 2026, down 31.11% year-on-year from -$91.3 million in Q1 2025, and down 185.07% quarter-over-quarter from -$22.1 million in Q4 2025.
Geron (GERN) Free Cash Flow (2010 - 2026) Analysis & Trends
Geron has disclosed Free Cash Flow across 17 years of filings, most recently posting -$62.9 million for Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$62.9 million, down 31.11% year-over-year; the trailing twelve-month figure through Mar 2026 was -$126.0 million (up 38.38% YoY), and the FY2025 annual result was -$111.0 million, up 49.37% from the prior year.
- Free Cash Flow came in at -$62.9 million for Q1 2026 at Geron, down from -$22.1 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$13.6 million in Q3 2025 to a low of -$62.9 million in Q1 2026.
- The 5-year median for Free Cash Flow is -$41.0 million (2023), against an average of -$40.6 million.
- Across the five-year window, Free Cash Flow plunged 80.13% in 2024 and soared 76.97% in 2025, its largest moves.
- Geron's Free Cash Flow stood at -$35.3 million in 2022, then decreased by 16.08% to -$41.0 million in 2023, then slipped by 6.83% to -$43.8 million in 2024, then surged by 49.62% to -$22.1 million in 2025, then tumbled by 185.07% to -$62.9 million in 2026.
- The last three Free Cash Flow figures came in at -$62.9 million (Q1 2026), -$22.1 million (Q4 2025), and -$13.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 63,220.27 |
| 10 | Geron | 729,618.77 | 729,618.77 | - | -62.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -62.91 Mn |
| Mar 31, 2026 | -62.91 Mn |
| Dec 31, 2025 | -22.07 Mn |
| Dec 31, 2025 | -22.07 Mn |
| Sep 30, 2025 | -13.58 Mn |
| Sep 30, 2025 | -13.58 Mn |
| Jun 30, 2025 | -27.42 Mn |
| Jun 30, 2025 | -27.42 Mn |
| Mar 31, 2025 | -47.98 Mn |
| Mar 31, 2025 | -47.98 Mn |
| Dec 31, 2024 | -43.80 Mn |
| Dec 31, 2024 | -43.80 Mn |
| Sep 30, 2024 | -58.94 Mn |
| Sep 30, 2024 | -58.94 Mn |
| Jun 30, 2024 | -53.68 Mn |
| Jun 30, 2024 | -53.68 Mn |
| Mar 31, 2024 | -62.87 Mn |
| Mar 31, 2024 | -62.87 Mn |
| Dec 31, 2023 | -41.00 Mn |
| Dec 31, 2023 | -41.00 Mn |